Literature DB >> 35680352

Population-based screening for acute SARS-CoV-2 infection using rapid antigen testing and the 5% pre-test probability. Is the specificity our problem?

José P Fernández-Vázquez1, Sofía Reguero1, Gloria Sánchez-Antolín2, Vicente Martín-Sánchez3.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35680352      PMCID: PMC9167941          DOI: 10.1016/j.eimce.2021.04.010

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin (Engl Ed)        ISSN: 2529-993X


× No keyword cloud information.
WHO's overall objective against COVID-19 is to control the pandemic situation by reducing the spread and the mortality associated with it. In order to slow down the transmission is the key to actively search for infected patients and subsequently isolate them and track and place their contacts in quarantine. The high percentage of asymptomatic patients together with the transmission before the onset of the symptoms make this search particularly complex. However, the screening strategy in the asymptomatic population is still controversial and its efficacy has not been well-established. The following are the results of a population-based screening for asymptomatic SARS-CoV-2 infected patients in a high-transmission community (cumulative incidence 14 days 908.05) and a low-traceability (16.55%). Through local social media, all inhabitants (31,068) in the municipality tested (San Andrés del Rabanedo, León, Spain) who did not have any symptoms and had not experienced SARS-CoV-2 infection over the last 3 months were contacted and summoned in a sport center. Nasopharyngeal samples were taken with a swab and tested using the Panbio COVID-19 Ag Rapid Test Device (Abbott Rapid Diagnostic Jena GmbH) (sensitivity 93.3% and specificity 99.4% according to manufacturer specifications). When invalid results occurred, performing a new test was strongly recommended. All positive cases were invited to allow for a new nasopharyngeal sample on the same day to perform a confirmatory rRT-PCR test. RNA extraction was performed with the Applied Biosystems MagMAX Viral/Pathogen kit using an automated instrument (Thermo Scientific™ KingFisher™) and rRT-PCR was carried out on a QuantStudio 5 system (Applied Biosystems) using a commercial kit (TaqPath COVID-19 CE-IVD RT-PCR Kit, Applied Biosystems) targeting ORF1ab, N and S genes of SARS-CoV-2. Rapid antigen testing (RAT) was carried out on 8187 people (Table 1 ). The result was invalid in six samples (none agreed to perform a second test), negative in 8127 and positive in 54 (apparent prevalence 0.66%). No significant differences were observed in the prevalence by sex or age. Of the 54 RAT positive participants, 51 were confirmed using rRT-PCR and three did not agree to have a new sample taken for confirmation. The positive predictive value of the RAT among those who agreed to a confirmatory test (51/51) was 100% as well as the specificity. In the worst scenario, if we assume that the three cases that did not access the rRT-PCR test were not confirmed, the specificity would have been 99.96% (95% CI 99.91–100%).
Table 1

Population distribution among surveyed, screened and rapid antigen test (RAT) positive individuals and SARS-CoV-2 infection prevalence detected by age and sex.

VariablesSurveyed
Screened
Apparent prevalence
No.%No.%Positives%95% CI
Age
 0–1724127.7655523.110.180.05–1.00
 18–6419,08061.41533528.0470.880.65–1.17
 65–7427948.9987231.220.230.03–0.82
 ≥7528819.2742114.610.240.01–1.32
 NR390112.5699825.630.300.06–0.88



Sex
 Men12,69240.85306224.1260.850.56–1.24
 Women14,47546.59412128.5250.610.39–0.89
 NR390112.5699825.630.300.06–0.88



Total
31,068100818726.35540.660.5–0.86

NR, not registered.

Population distribution among surveyed, screened and rapid antigen test (RAT) positive individuals and SARS-CoV-2 infection prevalence detected by age and sex. NR, not registered. In spite of being an area with significant community transmission, the pre-test probability in the investigated area was very low and far below the 5% recommended by WHO to carry out screenings. Nevertheless, a 100% specificity such as the one found in this screening program and also previously reported in a situation of low pre-test probability or among asymptomatic close contacts has resulted in a very acceptable performance as all cases detected were sources of SARS-CoV-2 infection. The average number of threshold cycles (Ct) in the positive cases which underwent rRT-PCR confirmation (considering Cts for N gene) is also worth pointing out. It was 19.0 (SD 3.3) ranging from 13.7 to 29.6, even lower than that reported by other authors in symptomatic patients. As previously proposed, samples containing small amounts of virus are most probably classified as negatives using RAT. According to this, even in the case of low sensitivity, it could be assumed that false negatives in the RAT are cases with low viral loads and therefore with a limited relevance as sources of infection.6, 7 To sum up, we report a high RAT specificity in a mass population screening in real life in a pre-test probability of less than 5%. Although the number of positive samples was limited, our results suggest a high yield of population screening strategies against COVID-19. Moreover, since the screening was organized by the Primary Care Services, all the isolating, care and tracing activities for cases and close contacts was interconnected.8, 9 Furthermore, as stated by Mina et al., it is not only the internal validity of a single diagnostic test which should be assessed; the context of its use and the assessment within a swiss cheese strategy should also be taken into account when setting pre-test probabilities and rethinking the 5% as being a turning point to implement population screening strategies in asymptomatic people.
  7 in total

1.  Rethinking Covid-19 Test Sensitivity - A Strategy for Containment.

Authors:  Michael J Mina; Roy Parker; Daniel B Larremore
Journal:  N Engl J Med       Date:  2020-09-30       Impact factor: 91.245

Review 2.  [Contact tracing in patients infected with SARS-CoV-2. The fundamental role of Primary Health Care and Public Health].

Authors:  J M Bellmunt; J A Caylà; J P Millet
Journal:  Semergen       Date:  2020-06-05

3.  Rapid Scaling Up of Covid-19 Diagnostic Testing in the United States - The NIH RADx Initiative.

Authors:  Bruce J Tromberg; Tara A Schwetz; Eliseo J Pérez-Stable; Richard J Hodes; Richard P Woychik; Rick A Bright; Rachael L Fleurence; Francis S Collins
Journal:  N Engl J Med       Date:  2020-07-22       Impact factor: 91.245

4.  Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms.

Authors:  Manuel Linares; Ramón Pérez-Tanoira; Ana Carrero; Juan Romanyk; Felipe Pérez-García; Peña Gómez-Herruz; Teresa Arroyo; Juan Cuadros
Journal:  J Clin Virol       Date:  2020-10-16       Impact factor: 3.168

5.  Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients.

Authors:  Ignacio Torres; Sandrine Poujois; Eliseo Albert; Javier Colomina; David Navarro
Journal:  Clin Microbiol Infect       Date:  2021-01-06       Impact factor: 8.067

6.  Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture.

Authors:  Andrew Pekosz; Valentin Parvu; Maggie Li; Jeffrey C Andrews; Yukari C Manabe; Salma Kodsi; Devin S Gary; Celine Roger-Dalbert; Jeffry Leitch; Charles K Cooper
Journal:  Clin Infect Dis       Date:  2021-01-20       Impact factor: 9.079

7.  Comparison of Rapid Antigen Tests for COVID-19.

Authors:  Seiya Yamayoshi; Yuko Sakai-Tagawa; Michiko Koga; Osamu Akasaka; Ichiro Nakachi; Hidefumi Koh; Kenji Maeda; Eisuke Adachi; Makoto Saito; Hiroyuki Nagai; Kazuhiko Ikeuchi; Takayuki Ogura; Rie Baba; Kensuke Fujita; Takahiro Fukui; Fumimaro Ito; Shin-Ichiro Hattori; Kei Yamamoto; Takato Nakamoto; Yuri Furusawa; Atsuhiro Yasuhara; Michiko Ujie; Shinya Yamada; Mutsumi Ito; Hiroaki Mitsuya; Norio Omagari; Hiroshi Yotsuyanagi; Kiyoko Iwatsuki-Horimoto; Masaki Imai; Yoshihiro Kawaoka
Journal:  Viruses       Date:  2020-12-10       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.